GEREF Drug Patent Profile
✉ Email this page to a colleague
When do Geref patents expire, and what generic alternatives are available?
Geref is a drug marketed by Emd Serono and Emd Serono Inc and is included in two NDAs.
The generic ingredient in GEREF is sermorelin acetate. There is one drug master file entry for this compound. Additional details are available on the sermorelin acetate profile page.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for GEREF?
- What are the global sales for GEREF?
- What is Average Wholesale Price for GEREF?
Summary for GEREF
| US Patents: | 0 |
| Applicants: | 2 |
| NDAs: | 2 |
| Raw Ingredient (Bulk) Api Vendors: | 25 |
| Patent Applications: | 296 |
| DailyMed Link: | GEREF at DailyMed |
US Patents and Regulatory Information for GEREF
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Emd Serono | GEREF | sermorelin acetate | INJECTABLE;INJECTION | 019863-001 | Dec 28, 1990 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Emd Serono Inc | GEREF | sermorelin acetate | INJECTABLE;INJECTION | 020443-001 | Sep 26, 1997 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Emd Serono Inc | GEREF | sermorelin acetate | INJECTABLE;INJECTION | 020443-002 | Sep 26, 1997 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for GEREF
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Emd Serono Inc | GEREF | sermorelin acetate | INJECTABLE;INJECTION | 020443-001 | Sep 26, 1997 | ⤷ Sign Up | ⤷ Sign Up |
| Emd Serono | GEREF | sermorelin acetate | INJECTABLE;INJECTION | 019863-001 | Dec 28, 1990 | ⤷ Sign Up | ⤷ Sign Up |
| Emd Serono Inc | GEREF | sermorelin acetate | INJECTABLE;INJECTION | 020443-002 | Sep 26, 1997 | ⤷ Sign Up | ⤷ Sign Up |
| Emd Serono Inc | GEREF | sermorelin acetate | INJECTABLE;INJECTION | 020443-001 | Sep 26, 1997 | ⤷ Sign Up | ⤷ Sign Up |
| Emd Serono Inc | GEREF | sermorelin acetate | INJECTABLE;INJECTION | 020443-002 | Sep 26, 1997 | ⤷ Sign Up | ⤷ Sign Up |
| Emd Serono | GEREF | sermorelin acetate | INJECTABLE;INJECTION | 019863-001 | Dec 28, 1990 | ⤷ Sign Up | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for GEREF
See the table below for patents covering GEREF around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Yugoslavia | 200083 | ⤷ Sign Up | |
| Finland | 843579 | ⤷ Sign Up | |
| Japan | H0689033 | ⤷ Sign Up | |
| Slovakia | 278537 | ⤷ Sign Up | |
| Germany | 3473764 | ⤷ Sign Up | |
| U.S.S.R. | 1477248 | CПOCOБ ПOЛУЧEHИЯ ПEПTИДOB (METHOD OF PRODUCING PEPTIDES) | ⤷ Sign Up |
| Canada | 1247601 | FACTEUR DE LIBERATION DE L'HORMONE DE CROISSANCE DU RAT ET ANALOGUES (RAT GRF AND ANALOGS) | ⤷ Sign Up |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
